Pharmaceutical - Women's Health, Oncology

Filter

Current filters:

Women's HealthOncology

Popular Filters

GSK withdraws European marketing authorization for ovarian cancer drug Votrient

GSK withdraws European marketing authorization for ovarian cancer drug Votrient

31-03-2014

UK pharma major GlaxoSmithKline has withdrawn its application to the European Medicines Agency for a…

GlaxoSmithKlineOncologyPharmaceuticalRegulationUKVotrientWomen's Health

Advaxis out-licenses ADXS-HPV to Biocon for emerging markets

Advaxis out-licenses ADXS-HPV to Biocon for emerging markets

23-01-2014

Indian biotech firm Biocon has entered into an exclusive licensing agreement for US cancer drug developer…

AdvaxisADXS-HPVAsia-PacificBioconIndiaLicensingOncologyPharmaceuticalWomen's Health

FDA approves Bayer’s Adempas; firm accelerates drug candidates

FDA approves Bayer’s Adempas; firm accelerates drug candidates

09-10-2013

The US Food and Drug Administration late yesterday approved Adempas (riociguat), developed by German…

AdempasBayerCardio-vascularcopanlisibfinerenoneNorth AmericaOncologyPharmaceuticalRegulationResearchRespiratory and PulmonaryWomen's Health

Aspirin may lower risk of melanoma, researchers suggest

11-03-2013

A new study has found that women who take aspirin have a reduced risk of developing melanoma - and that…

AspirinOncologyPharmaceuticalResearchWomen's Health

Arzerra and ospemifene NDAs submitted in Japan

02-05-2012

UK pharma giant GlaxoSmithKline (LSE: GSK) and Danish company Genmab A/S (OMX: GEN) have submitted a…

ArzerraAsia-PacificGenmabGlaxoSmithKlineOncologyospemifenePharmaceuticalQuatRx PharmaRegulationShionogiWomen's Health

UK government to switch from Cervarix to Gardasil for HPV vaccination

25-11-2011

As of next September, a different vaccine will be used in the HPV vaccination program to protect girls…

CervarixEuropeGardasilGlaxoSmithKlineHealthcareMerck & CoOncologyPharmaceuticalPricingSanofiSanofi Pasteur MSDVaccinesWomen's Health

Parexel

Parexel

Back to top